COSMOS Pharmaceutical Corporation
CSMYF · OTC
5/31/2025 | 5/31/2024 | 5/31/2023 | 5/31/2022 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | $42,372,000 | $24,454,000 | $32,773,000 | $33,048,000 |
| Dep. & Amort. | $22,229,000 | $19,924,000 | $17,368,000 | $15,110,000 |
| Deferred Tax | $0 | $0 | $0 | $0 |
| Stock-Based Comp. | $0 | $0 | $0 | $0 |
| Change in WC | -$8,567,000 | $7,437,000 | $10,164,000 | -$1,203,000 |
| Other Non-Cash | -$3,567,000 | $3,360,000 | -$5,871,000 | -$14,761,000 |
| Operating Cash Flow | $52,467,000 | $55,175,000 | $54,434,000 | $32,194,000 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$53,326,000 | -$55,810,000 | -$46,636,000 | -$43,497,000 |
| Net Acquisitions | $0 | $0 | $46,000 | $1,519,000 |
| Inv. Purchases | $0 | $0 | -$500,000 | -$713,000 |
| Inv. Sales/Matur. | $0 | $0 | $428,000 | $407,000 |
| Other Inv. Act. | -$2,122,000 | -$1,519,000 | -$2,451,000 | -$1,433,000 |
| Investing Cash Flow | -$55,448,000 | -$57,329,000 | -$49,113,000 | -$43,717,000 |
| Financing Activities | – | – | – | – |
| Debt Repay. | $14,918,000 | $15,207,000 | $8,372,000 | -$1,186,000 |
| Stock Issued | $0 | $0 | $0 | $0 |
| Stock Repurch. | -$2,000 | $0 | $0 | -$2,000 |
| Dividends Paid | -$4,959,000 | -$4,659,000 | -$3,266,000 | -$3,266,000 |
| Other Fin. Act. | -$2,240,000 | -$2,021,000 | -$1,861,000 | -$1,768,000 |
| Financing Cash Flow | $7,717,000 | $8,527,000 | $3,245,000 | -$6,222,000 |
| Forex Effect | $0 | $0 | $0 | -$1,000 |
| Net Chg. in Cash | $4,737,000 | $6,373,000 | $8,566,000 | -$17,746,000 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $52,301,000 | $45,928,000 | $37,362,000 | $55,108,000 |
| End Cash | $57,038,000 | $52,301,000 | $45,928,000 | $37,362,000 |
| Free Cash Flow | -$859,000 | -$635,000 | $7,798,000 | -$11,303,000 |